Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology (PBYI) reported Q2 2026 revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million. GAAP net income was $8.2 million ($0.16/share). The company raised full-year net product revenue guidance to $205 million to $209 million and net income to $17 million to $20 million, while lowering royalty guidance to $19 million to $22 million.
How this was made
The 30-second read
Why it matters
The key tradable elements are the raised full-year net product revenue and net income guidance, the Q3 net product revenue and net income outlook, and updated clinical trial protocol changes for alisertib. Offsetting risks include a potential royalty-rate reduction under the China sublicense when generics reach a specified market share threshold, plus uncertainty from evolving trade policies.
Market read
Traders can reprice Puma’s near-term earnings trajectory based on raised guidance and Q3 outlook, while monitoring royalty and policy risks that could affect later-period profitability.
What to watch
Gross-to-net adjustment rose to 27.9% due to higher Medicaid share, so net revenue quality may depend on continued payer mix stability and inventory drawdown dynamics.
Background
Puma Biotechnology reported Q2 2026 results and provided full-year and Q3 2026 guidance, centered on NERLYNX commercial performance and alisertib clinical development updates.
Ticker impact
Puma raised full-year net product revenue guidance to $205M-$209M and net income to $17M-$20M on Q2 NERLYNX demand strength.
Likely positive bias for shares into the next earnings window, with volatility around royalty-rate threshold and evolving trade-policy commentary.
The article provides specific, time-bound guidance changes plus operational KPIs (bottle sales, prescriptions, GTN, inventory). It also flags late-2026/2027 royalty-rate reduction risk and potential trade-policy impacts, which can offset the guidance raise.
Market effects
Reinforces demand durability for an oncology commercial asset (NERLYNX) and highlights how GTN and Medicaid mix drive net revenue sensitivity.
US-focused demand and Medicaid share changes can influence sentiment toward US oncology commercial execution.
China sublicense royalty mechanics and trade-policy uncertainty underscore cross-border regulatory and policy risk for oncology royalties.
Counterpoint
The guidance raise may be partially offset by a potential late-2026/2027 royalty-rate reduction tied to generic market share thresholds, which could pressure future margins.
Key entities
- companyPuma Biotechnology
Reported Q2 2026 results, raised full-year guidance, and updated NERLYNX commercial KPIs and alisertib trial plans.
- productNERLYNX (neratinib)
Commercial oncology drug driving net product revenue and demand metrics in the quarter.
- investigational drugalisertib
Aurora kinase A inhibitor in clinical trials; protocol amendments and planned initiation of ALISCA-Lung2 were discussed.
